Prosecution Insights
Last updated: November 04, 2026

Glenmark Specialty S A

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days

Analysis

Glenmark Specialty S A holds a patent portfolio in the Biotechnology & Pharmaceuticals technology area. There is currently 1 pending office action for this company. This indicates a singular active matter in the current prosecution cycle, reflecting a targeted approach to their pharmaceutical intellectual property.

The portfolio's activity is limited to 1 distinct examiner and 1 distinct art unit. This concentration suggests that the company's current patenting efforts are focused on a specific area of technology. Working within 1 distinct art unit provides a consistent environment for the prosecution of these assets, as the company only needs to navigate the standards of a single administrative group.

RAMACHANDRAN, UMAMAHESWARI is the busiest examiner for Glenmark Specialty S A. This examiner is handling the 1 pending office action currently active. The progress of the company's patent applications is currently tied to the specific examination process and technical feedback provided by this individual examiner.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
0
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
1
Medium (100%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Double-patenting + other1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
RAMACHANDRAN, UMAMAHESWARI 1 54.9% +53.7%

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18392033 TREATMENT OF ALLERGIC RHINITIS USING A COMBINATION OF MOMETASONE AND OLOPATADINE RAMACHANDRAN, UMAMAHESWARI —

Top Art Units

Art UnitApps
1627 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18392033 TREATMENT OF ALLERGIC RHINITIS USING A COMBINATION OF MOMETASONE AND OLOPATADINE RAMACHANDRAN, UMAMAHESWARI 1627 §103§112DP Final Rejection — Pending Dec 21, 2023

Managing Glenmark Specialty S A's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Glenmark Specialty S A have?

Glenmark Specialty S A has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Glenmark Specialty S A applications?

Umamaheswari Ramachandran has the most, with 1 of Glenmark Specialty S A's pending office actions.

What technology area are Glenmark Specialty S A's patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month